Drug Approval | October 26, 2021
Glenmark launches novel fixed-dose combination for diabetes
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Subscribe To Our Newsletter & Stay Updated
